Kura Oncology (KURA) awards director stock options at $8.77 strike

Rhea-AI Filing Summary

Kura Oncology, Inc. director Faheem Hasnain reported receiving an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. Following this grant, Hasnain holds options for 35,000 shares. The award vests in full on the one-year anniversary of the grant date, making it a standard equity compensation grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hasnain Faheem

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 options Exercise price: $8.77/share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 35,000 options Grant of option to purchase common stock

Exercise price $8.77/share Conversion or exercise price of granted options

Expiration date June 3, 2036 Option expiration date

Underlying shares 35,000 shares Common stock underlying the option grant

Post-grant option holdings 35,000 options Total options owned following this transaction

Key Terms

Option to purchase common stock, Grant, award, or other acquisition, vests in full, exercise price

4 terms

Option to purchase common stock financial

"security_title: "Option to purchase common stock" for the derivative award"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" describing the option grant"

vests in full financial

"footnote: "This option vests in full on the one year anniversary""

exercise price financial

"conversion_or_exercise_price of 8.7700 per share for the option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasnain Faheem

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kura Oncology (KURA) disclose in this Form 4 for Faheem Hasnain?

Kura Oncology reported that director Faheem Hasnain received an option grant for 35,000 shares of common stock. The award is a compensation grant, not an open-market trade, and gives him the right to buy shares at a preset exercise price.

How many Kura Oncology (KURA) stock options were granted to Faheem Hasnain?

Faheem Hasnain was granted options to purchase 35,000 shares of Kura Oncology common stock. These options represent a new equity award and bring his reported option holdings to 35,000 shares immediately after the transaction, according to the Form 4 filing details.

What is the exercise price and expiration date of Faheem Hasnain’s Kura (KURA) options?

The granted options have an exercise price of $8.77 per share and expire on June 3, 2036. This means Hasnain can choose to buy up to 35,000 shares at $8.77 any time before the stated expiration date, once vested.

When do Faheem Hasnain’s newly granted Kura Oncology (KURA) options vest?

The options granted to Faheem Hasnain vest in full on the one-year anniversary of the grant date. Until that vesting date, the options cannot be exercised, but after vesting he can exercise all 35,000 options at the fixed exercise price.

Is Faheem Hasnain’s Kura Oncology (KURA) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant of derivative securities, not an open-market stock purchase. Hasnain received an option award coded as a grant or other acquisition, giving him rights to buy 35,000 shares later at $8.77 per share, subject to vesting.